Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Minor: Lunsekimig · Chronic Obstructive Pulmonary Disease (COPD) Trial sites expanded: 8 → 16 locations
- Minor: EYE201/MK-8748 · Macular Degeneration (MK-8748-003) Trial sites expanded: 71 → 121 locations
- Minor: Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants Trial sites expanded: 8 → 20 locations
- Minor: SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) Trial sites expanded: 61 → 75 locations
- Minor: ALKS 2680 · Narcolepsy Type 2 Trial sites expanded: 44 → 61 locations
- Minor: EloraTZP · Obesity Without Type 2 Diabetes Trial sites expanded: 155 → 161 locations
- Minor: Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Breast Cancer (MK-2870-032) Trial sites expanded: 335 → 338 locations
- Minor: Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Urothelial Cancer (MK-2870-031) Trial sites expanded: 111 → 117 locations
- Minor: ALKS 2680 · Narcolepsy Type 1 Trial sites expanded: 42 → 66 locations
- Minor: GB-0895 Adjunctive Therapy in Adults and · Severe Uncontrolled Asthma (SOLAIRIA-2) Trial sites expanded: 158 → 166 locations
- Minor: Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD) Trial sites expanded: 50 → 56 locations
- Minor: EYE201/MK-8748 · Macular Degeneration (MK-8748-002) Trial sites expanded: 132 → 148 locations
- Minor: New Formulation of Oral Cladribine Compared With Placebo · Generalized Myasthenia Gravis (MyClad) Trial sites expanded: 153 → 159 locations
- Minor: Canvuparatide Compared With Placebo · Hypoparathyroidism Trial sites expanded: 22 → 28 locations
- Minor: Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Trial sites expanded: 168 → 174 locations
- Minor: Xywav Expanded Dosing vs Placebo · Narcolepsy or IH Trial sites expanded: 15 → 27 locations
- Minor: ALKS 2680 · Narcolepsy Type 1 (Brilliance NT1 - 304) Trial sites expanded: 20 → 53 locations
- Minor: Outcomes of Pemvidutide in MASH Trial sites expanded: 9 → 62 locations
- Minor: Efimosfermin Compared With Placebo · Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) Trial sites expanded: 35 → 39 locations
- Minor: BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer Trial sites expanded: 52 → 77 locations
- Minor: Fenfluramine Hydrochloride in Rett Syndrome Trial sites expanded: 40 → 46 locations
- Minor: Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections · Multiple Myeloma Trial sites expanded: 65 → 68 locations
- Minor: Efimosfermin Alfa Compared With Placebo · Alcohol-related Liver Disease (ALD) Trial sites expanded: 13 → 17 locations
- Minor: Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy · HER2-positive Breast Cancer Trial sites expanded: 53 → 60 locations
- Minor: PIPE 791 · Idiopathic Pulmonary Fibrosis Trial sites expanded: 108 → 111 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates